KVKerstin Noelle Vokinger

Kerstin Noelle Vokinger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kerstin Noelle Vokinger has a total of 81 co-authors. Here are the top co-authors by number of shared publications:

  • Aaron S. Kesselheim

    Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

    6 shared publications
  • Miquel Serra-Burriel

    Epidemiology Biostatistics and Prevention Institute University of Zurich Zurich Switzerland

    6 shared publications
  • Aaron S Kesselheim

    Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, USA

    5 shared publications
  • Aaron Seth Kesselheim

    Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts USA

    5 shared publications
  • Camille E.G. Glaus

    5 shared publications
  • Miquel Serra-Burriel

    Faculty of Law, University of Zurich, Zurich, Switzerland

    4 shared publications

Latest Publications

  • Review Duration and Therapeutic Value of Cancer Drugs Granted Priority Versus Nonpriority Review in the United States, European Union, and Switzerland (2010-2024)

    by Simon Hediger, Lara Welti, Camille E.G. Glaus, Ulrich-Peter Rohr, Kerstin Noelle Vokinger

    PURPOSE: The objective of priority review is to expedite the review duration for drugs that provide significant improvements. We analyzed the duration of regulatory review of cancer drugs granted priority versus nonpriority review and differences in the proportion of cancer drugs with high therapeutic value granted priority versus nonpriority review in the United States, European Union, and Switzerland. METHODS: In this cross-sectional study, we used US Food and Drug Administration’s (FDA), European Medicines Agency's (EMA), and Swissmedic's databases to identify all new cancer drugs approved in 2010-2024, their submission and approval dates, and approval pathways. European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) and ESMO-Magnitude of Clinical Benefit Scale for Haematological Malignancies scores were calculated to assess their therapeutic value. We applied summary statistics (medians and IQR) to describe differences in review duration for priority versus nonpriority review. Review duration was calculated from submission to approval date. For estimated differences in proportions of high therapeutic value scores for drugs granted priority versus nonpriority review, we calculated classical normal 95% CIs. RESULTS: In all, 144 (86%) of 168 cancer drugs were granted priority review by the FDA, 37 (25%) of 147 by EMA, and 37 (28%) of 132 by Swissmedic. Of those, the FDA reviewed 30%, EMA 5%, and Swissmedic 49% within the required time period; review duration was similar for drugs with high and low therapeutic value. The difference in the proportion of high value scores between priority and nonpriority review was –4% (95% CI, –20 to 13) for the FDA, 22% (95% CI, 6 to 38) for EMA, and 17% (95% CI, <1 to 33]) for Swissmedic. CONCLUSION: It could be beneficial for patients if agencies applied more scrutiny in the selection of which cancer drugs to grant priority review. Such drugs should have a high therapeutic value, and their review should be completed in a timely manner to enable quicker access to important cancer drugs for patients. Although the FDA would need to take the most substantial steps, EMA and Swissmedic could also improve their systems.

  • Open Access

    Quantification of Age and Sex Ratio Differences between Trial and Target Population for New Drugs

    by Miquel Serra‐Burriel, Paul Schlossmacher, Kerstin Noelle Vokinger

    Clinical trials are essential to understand the benefit‐harm profile of new drugs. Lack of adequate representation in age and sex ratio in clinical trials can result, for example, in higher side effects for underrepresented patients. We quantified differences in age and sex ratios between trial and target populations of new drugs approved by the FDA 2011–2022. We used the FDA's database to identify all new drugs and pivotal randomized trials. Information for average age and sex ratio was obtained from clinicaltrials.gov . Each trial's indication was matched with prevalence estimates of the targeted diseases from the global burden of disease study. A total of 458 drugs (773 trials) were included. The trial populations were significantly younger, on average 4.8 years (95% CI [5.4 years, 4.2 years]), and the female ratio significantly smaller, on average 4.3 percentage points (95% CI [5.4 pp, 3.3 pp]), than the target populations. For diseases with average patient age below 40, the trial population was significantly older than the target population but significantly younger 40 years and older. For diseases with average age between 30 and 39, the female ratio in the trial population was significantly higher than in the target population but significantly lower 50 and older. Better age and sex ratio representation in the trial population is indicated to improve safety and efficacy for patients. Trials targeting diseases below 40 should enroll younger participants and increase their male ratio, while the opposite is true for trials targeting diseases with an older age.

  • Open Access

    Therapeutic benefit of the most expensive drugs covered by Medicare and Medicaid

    by Tiffany Enxia Jiang, Reshma Ramachandran, Kerstin N. Vokinger, Joseph S. Ross

    The United States began drug pricing negotiations in 2024 under the Affordable Care Act. Evaluating the therapeutic benefit of drugs will help guide pricing decisions and are an opportunity to improve healthcare affordability. We conducted a cross-sectional study of the 50 most expensive drugs by dosage unit covered by Medicare Part B, Medicare Part D, and Medicaid in 2022. We reported their level of clinical benefit as evaluated by health technology assessment agencies in France and Germany, their level of innovation as rated by the Food and Drug Administration of the United States, and their safety and effectiveness ratings as measured by Prescrire International, an independent French organisation that evaluates medicines. Our study found that among the 50 most expensive drugs in the U.S. covered by Medicare and Medicaid in 2022, 28 (56%) were rated by French and German HTAs as having low therapeutic benefit and most (n = 20; 40%) were rated by Prescrire International as having poor effectiveness-safety ratings. Almost all (n = 48; 96%) drugs were ineligible under current exclusion criteria for price negotiations. Many of the most expensive drugs were rated as having low added clinical benefit. As the US begins price negotiations under the Inflation Reduction Act, understanding the clinical value of drugs may help inform debates over drug affordability.


  • Differences Between Trial Populations and Approved Label Populations of New Drugs in the United States and Europe (2012 to 2023)

    by Kerstin N. Vokinger, Miquel Serra-Burriel, Camille E.G. Glaus, Lara Welti, Joseph S. Ross, Aaron S. Kesselheim

    Drugs are approved when their benefits outweigh their risks based on the results of clinical trials. It remains unclear how often regulatory agencies extrapolate or restrict the approval compared with the trial. To analyze the differences in the characteristics of enrolled patients between trial populations and approved label populations in the United States, European Union (EU), and Switzerland for new drugs. Cross-sectional study. Inclusion of all new drugs that were approved by all 3 agencies from 2012 to 2023 and comparison of trial populations with the approved label populations. Aggregated and anonymized patient data included in trial data and approved label information were analyzed. The eligibility criteria of the trial population with the approved label population in the United States, EU, and Switzerland were compared for 5 categories: age, disease subtype, disease severity, patient fitness, and prior therapy. Linear regression models were performed, and the proportions of more extensive and more restrictive evaluations were determined. 263 drugs (278 indications) were included in the study cohort. Overall, approved label populations were broader than trial populations and more pronounced in the United States compared with the EU and Switzerland. Patient fitness was the most often at variance with 276 approved indications (99.3% [95% CI, 99.2% to 99.4%]) in the United States and EU, and 275 (98.9% [CI, 98.8% to 99%]) in Switzerland, followed by disease severity with 143 approved indications (51% [CI, 49% to 54%]) in the United States, 119 (43%, [CI, 40% to 46%]) in the EU, and 111 (40% [CI, 37% to 43%]) in Switzerland. Reporting of trial eligibility criteria lacked uniformity. Postapproval trials and surveillance are indicated for drugs for which broadening has occurred to ensure safety and efficacy for patient subpopulations that were not included in the trials. Kaiser Permanente Institute of Health Policy; Swiss National Science Foundation (SNSF).


  • Open Access

    Generic competition and price developments in the USA, Germany and Switzerland (2007–2023): a longitudinal observational study

    by Simon Hediger, Luca Locher, Kerstin Noëlle Vokinger

    Introduction: Drug expenditure has increased over the past years in the USA and Europe, mainly driven by originator drugs. Generic drugs have a substantial cost-saving potential. We analysed the number of generic competitors entering the market over time, distribution of market share between originator drugs and their generic competitors and association between the number of generic competitors and price changes of originator and generic drugs in the USA, Germany and Switzerland. Methods: In this longitudinal observational study, we included all originator drugs and their corresponding generic competitors with market entry between 2007 and 2023 in the USA, Germany and Switzerland from the IQVIA database. We extracted quarterly price and sales volume data for the same study period from the IQVIA database. Descriptive statistics and regression analyses were conducted to answer the research questions. Results: 530 active substances in the USA, 406 in Germany and 108 in Switzerland were included. 3 years after competition start, an average of four generic competitors entered the market in the USA, 7.6 in Germany and 3.3 in Switzerland. An increase in the number of generic competitors was associated with an increase in average generic market share. On average, the generic market share reached 90% after the entry of five generic drugs in the USA and nine in Germany, and was not reached in Switzerland. An association between the number of competitors and relative price decrease of generic drugs was observed in all three countries. This association was also observed for originator drugs in Switzerland and Germany, but not in the USA. Conclusions: The findings indicate that policies targeting market entry and prices of generic drugs would be helpful in all three countries. More research is needed to assess the impact of previous and future policies.


  • Lieferengpässe bei Arzneimitteln

    by Kerstin Noëlle Vokinger, Wolf-Dieter Ludwig

  • Regulation of AI: Learnings from Medical Education

    by Kerstin N. Vokinger, Derek R. Soled, Raja-Elie E. Abdulnour